Cedars-Sinai, UA Cancer Center study shows how missing pieces of Y chromosome drive cancer in men - The Cancer Letter

Eric Cantor named president and CEO of PhRMA - The Cancer Letter

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion - The Cancer Letter

Sanya Springfield to receive AACR Distinguished Public Service Award - The Cancer Letter

James Yu named associate director for clinical research at Dartmouth Cancer Center - The Cancer Letter

Decipher prostate test predicts benefit from adding hormone therapy to radiation, phase III trial shows - The Cancer Letter

FDA approves Ponlimsi, a biosimilar for preventing fractures in prostate and breast cancer patients - The Cancer Letter

COA survey finds high bispecific therapy adoption among community oncology practices - The Cancer Letter

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - The Cancer Letter

When did stage 3B lung cancer become “early stage”? - The Cancer Letter

Colorectal Cancer Alliance appoints four new board members - The Cancer Letter

Blood test could guide future treatment in Ewing sarcoma, Dana-Farber study finds - The Cancer Letter

Erin Geddis Cummings, Bradley Zebrack receive Cancer Nation’s 2026 Ellen L. Stovall Award - The Cancer Letter

Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants - The Cancer Letter

FDA grants Priority Review to perioperative IMFINZI + enfortumab vedotin for muscle-invasive bladder cancer - The Cancer Letter

HHS issues direct final rule to reduce reliance on animal testing - The Cancer Letter

PDS0101 + pembrolizumab in HPV16+ R/M head and neck cancer show anti-tumor activity, VERSATILE-002 phase II study finds - The Cancer Letter

How biology is reshaping breast cancer care - The Cancer Letter

Rutika Mehta named director of upper GI medical oncology at NYU - The Cancer Letter

When did stage 3B lung cancer become “early stage”? - The Cancer Letter

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds - The Cancer Letter

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - The Cancer Letter

UNM Comprehensive Cancer Center earns NCI redesignation - The Cancer Letter

Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants - The Cancer Letter

FDA approves Lyrfigtu for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma - The Cancer Letter

FDA approves belzutifan in combination with lenvatinib for advanced RCC with a clear cell component - The Cancer Letter

When did stage 3B lung cancer become “early stage”? - The Cancer Letter